GlassScriptPhysician profile
Andrew J Simpson
NPI 1417134008
$9,970.38
in general payments reported to CMS, 2019-2025
45 companies · $2,291 in 2025
The $2,291 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $906 · 2021: $1,138 · 2022: $718 · 2023: $1,367 · 2024: $2,634 · 2025: $2,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,272 · Education: $19.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,272.34 |
| Education | $19.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,122.07 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Janssen Biotech, INC. | $1,430.17 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,046.02 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $676.47 | 2019-2025 | Entyvio, Gattex |
| Lilly USA, LLC | $518.74 | 2023-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $460.03 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $327.54 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $268.28 | 2019-2024 | Dificid |
| Romark Laboratories, Lc | $257.41 | 2019-2020 | |
| Pfizer INC. | $237.54 | 2019-2025 | |
| Madrigal Pharmaceuticals | $235.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $222.54 | 2020-2025 | Epclusa, Livdelzi |
| Ardelyx, INC. | $211.19 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $201.15 | 2022-2025 | |
| Daiichi Sankyo INC. | $191.72 | 2019-2023 | Injectafer |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $172.35 | 2023-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $156.02 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $152.20 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $115.24 | 2019-2024 | Linzess |
| Organon LLC | $85.32 | 2024-2025 | Hadlima, Renflexis |
| Amag Pharmaceuticals, INC. | $76.35 | 2019-2021 | |
| Redhill Biopharma INC. | $73.06 | 2021-2024 | Talicia |
| Amgen INC. | $67.42 | 2020-2023 | Amjevita, Avsola |
| Celltrion USA INC. | $63.72 | 2024-2025 | Vegzelma |
| Csl Behring | $60.27 | 2021-2023 | Kcentra |
| Aimmune Therapeutics, INC. | $53.43 | 2024-2025 | Zenpep |
| Ucb, INC. | $46.64 | 2019 | |
| Alfasigma USA, INC. | $42.58 | 2020 | |
| Fresenius Kabi USA, LLC | $37.37 | 2023-2024 | Idacio |
| Xeris Pharmaceuticals, INC. | $36.90 | 2023 | Keveyis |
| Nestle Healthcare Nutrition INC. | $35.38 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $33.53 | 2019 | |
| Ferring Pharmaceuticals INC. | $28.66 | 2023-2024 | Rebyota |
| Qol Medical, LLC | $25.05 | 2024 | Sucraid |
| Allergan, INC. | $24.34 | 2019 | |
| Braintree Laboratories, INC. | $22.59 | 2024 | Suflave, Sutab |
| Biogen, INC. | $21.82 | 2019 | |
| Tempus Ai, INC | $21.14 | 2024 | |
| Vivus LLC | $20.65 | 2025 | Pancreaze |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Novo Nordisk INC | $19.24 | 2025 | Wegovy |
| Shionogi INC | $17.25 | 2019 | |
| Capsovision, INC. | $16.94 | 2023 | Capsocam Plus |
| Evoke Pharma, INC. | $13.48 | 2025 | |
| Intra-Sana Laboratories | $5.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.